Related Experiment Video
Updated: Feb 4, 2026

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting
Published on: June 21, 2024
Adherence to pediatric acute chemotherapy-induced nausea and vomiting guidelines in Canadian hospitals
Krista McKinnon1, Jennifer Jupp1, Sunita Ghosh2
1Pharmacy Services, Alberta Children's Hospital, Alberta Health Services, Calgary, Canada.
Insights
Pediatric cancer patients show low adherence to chemotherapy-induced nausea and vomiting (CINV) guidelines. This resulted in poor CINV control, highlighting a need for improved treatment strategies in pediatric oncology care.
Area of Science:
- Pediatric Oncology
- Clinical Pharmacy
- Evidence-Based Medicine
Background:
- Chemotherapy-induced nausea and vomiting (CINV) significantly affects pediatric cancer patients' quality of life.
- Recent guidelines for CINV classification and prevention in children have been endorsed by major pediatric oncology organizations.
Purpose of the Study:
- To evaluate the adherence rates to pediatric CINV guidelines across four Canadian pediatric oncology centers.
- To assess the impact of guideline adherence on CINV control in children receiving highly or moderately emetogenic chemotherapy.
Main Methods:
- A multicenter chart review was conducted for 204 pediatric patients receiving their first chemotherapy course (highly emetogenic chemotherapy [HEC] or moderately emetogenic chemotherapy [MEC]) between 2012 and 2015.
- Guideline adherence was assessed based on antiemetic-only guideline adherence (AGA) and complete guideline adherence (CGA), considering medication, dose, frequency, and duration.
Main Results:
- Overall guideline adherence was low: 29% for AGA and 2% for CGA.
- Vomiting occurred in 24% of AGA patients versus 34% of non-AGA patients (P=0.13).
- Complete CINV control in the first 24 hours was achieved by 37% of HEC AGA patients vs. 45% of non-AGA patients (P=0.31), and 80% of MEC AGA patients vs. 24% of non-AGA patients (P=0.02).
Conclusions:
- Adherence to pediatric CINV guidelines was suboptimal across participating institutions.
- Varied implementation strategies for CINV guidelines were observed among centers.
- Low complete CINV control rates and high instances of emesis indicate that pediatric patients are not receiving optimal antiemetic treatment.
Background:
Chemotherapy-induced nausea and vomiting (CINV) impacts quality of life for patients. Guidelines for emetogenicity classification and prevention of CINV in children were recently published and endorsed by pediatric oncology organizations.
Procedure:
A multicenter chart review was performed at four Canadian pediatric oncology centers examining rates of prescribing adherence to CINV guidelines between January 2012 and December 2015. Eligible patients received their first chemotherapy course of highly emetogenic chemotherapy (HEC) or moderately emetogenic chemotherapy (MEC).
Results:
Guideline adherence was described in 204 patients as antiemetic-only guideline adherence (AGA; examined medication/class prescribed only) and complete guideline adherence (CGA; examined medication/class, dose, frequency, and duration prescribed). Adherence was 29% (HEC 30%, MEC 19%, P = 0.1) and 2% for AGA and CGA patients, respectively. Vomiting in the first 24 h was experienced by 24% of AGA and 34% of non-AGA patients (P = 0.13), with mean breakthrough medication doses similar between AGA and non-AGA groups (HEC 1.8 vs 1.5, P = 0.45; MEC 3 vs 1.42, P = 0.35). In the first 24 h, HEC AGA patients achieved a complete control rate of 37% vs 45% for non-AGA patients (P = 0.31), while patients receiving AGA therapy for MEC achieved a complete control rate of 80% vs 24% for non-AGA patients (P = 0.02).
Conclusions:
Adherence to guidelines was low across all four pediatric institutions. Each center used different approaches to implement pediatric CINV guidelines. Complete CINV control was low, with reports of emesis high, indicating that patients are not receiving optimal treatment.
Related Concept Videos
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Two synthetic agonists of THC,...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Hospitals-II
Nurses that work in...
Hospitals-I

